Search

Your search keyword '"Frigoli, Enrico"' showing total 10 results
Start Over Author "Frigoli, Enrico" Publication Year Range This year
10 results on '"Frigoli, Enrico"'

3. Reproducibility of an artificial intelligence optical coherence tomography software for tissue characterization: Implications for the design of longitudinal studies

Author

Garg, Mohil, Garcia-Garcia, Hector M., Calderón, Andrea Teira, Gupta, Jaytin, Sortur, Shrayus, Levine, Molly B., Singla, Puneet, Picchi, Andrea, Sardella, Gennaro, Adamo, Marianna, Frigoli, Enrico, Limbruno, Ugo, Rigattieri, Stefano, Diletti, Roberto, Boccuzzi, Giacomo, Zimarino, Marco, Contarini, Marco, Russo, Filippo, Calabro, Paolo, Andò, Giuseppe, Varbella, Ferdinando, Garducci, Stefano, Palmieri, Cataldo, Briguori, Carlo, Sánchez, Jorge Sanz, and Valgimigli, Marco

Published
2024
Full Text
View/download PDF

4. Geographical variations in the effectiveness and safety of abbreviated or standard antiplatelet therapy after PCI in patients at high bleeding risk

Author

Ozaki, Yukio, primary, Hong, Sung-Jin, additional, Heg, Dik, additional, Frigoli, Enrico, additional, Vranckx, Pascal, additional, Morice, Marie-Claude, additional, Chevalier, Bernard, additional, Onuma, Yoshinobu, additional, Windecker, Stephan, additional, Di Biasi, Maurizio, additional, Whitbourn, Robert, additional, Dudek, Dariusz, additional, Raffel, Owen Christopher, additional, Shimizu, Kiyokazu, additional, Calabrò, Paolo, additional, Fröbert, Ole, additional, Cura, Fernando, additional, Berg, Jurrien ten, additional, Smits, Pieter C., additional, and Valgimigli, Marco, additional

Published
2024
Full Text
View/download PDF

5. Geographical variations in the effectiveness and safety of abbreviated or standard antiplatelet therapy after PCI in patients at high bleeding risk

Author

Ozaki, Yukio, Hong, Sung-Jin, Heg, Dik, Frigoli, Enrico, Vranckx, Pascal, Morice, Marie-Claude, Chevalier, Bernard, Onuma, Yoshinobu, Windecker, Stephan, Di Biasi, Maurizio, Whitbourn, Robert, Dudek, Dariusz, Raffel, Owen Christopher, Shimizu, Kiyokazu, Calabrò, Paolo, Fröbert, Ole, Cura, Fernando, Berg, Jurrien Ten, Smits, Pieter C., Valgimigli, Marco, Ozaki, Yukio, Hong, Sung-Jin, Heg, Dik, Frigoli, Enrico, Vranckx, Pascal, Morice, Marie-Claude, Chevalier, Bernard, Onuma, Yoshinobu, Windecker, Stephan, Di Biasi, Maurizio, Whitbourn, Robert, Dudek, Dariusz, Raffel, Owen Christopher, Shimizu, Kiyokazu, Calabrò, Paolo, Fröbert, Ole, Cura, Fernando, Berg, Jurrien Ten, Smits, Pieter C., and Valgimigli, Marco

Abstract

In high-bleeding risk (HBR) patients, non-inferiority of 1-month dual antiplatelet therapy (APT) to treatment continuation for ≥2 additional months for the occurrence of net and major adverse clinical events after drug-eluting stent implantation was showed in the MASTER DAPT trial.1 A significant reduction in bleeding was also noted. However, whether these treatment effects of APT are consistent across geographical regions remains uncertain. In the present analyses, the effects of abbreviated or standard APT on the 1-year occurrence of net and major adverse clinical events and bleeding were consistent across geographical regions (Europe, East Asia, and others) [NCT03023020]., The study was sponsored by the European Cardiovascular Research Institute, a nonprofit organization, and received grant support from Terumo.

Published
2024
Full Text
View/download PDF

6. Geographical Variations in the Effectiveness and Safety of Abbreviated or Standard Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients at High Bleeding Risk

Author

Ozaki, Yukio, Hong, Sung-Jin, Heg, Dik, Frigoli, Enrico, Vranckx, Pascal, Morice, Marie-Claude, Chevalier, Bernard, Onuma, Yoshinobu, Windecker, Stephan, Di Biasi, Maurizio, Whitbourn, Robert, Dudek, Dariusz, Raffel, Owen Christopher, Shimizu, Kiyokazu, Calabrò, Paolo, Fröbert, Ole, Cura, Fernando, Berg, Jurrien Ten, Smits, Pieter C., and Valgimigli, Marco

Published
2024
Full Text
View/download PDF

9. Abbreviated or Standard Dual Antiplatelet Therapy by Sex in Patients at High Bleeding Risk: A Prespecified Secondary Analysis of a Randomized Clinical Trial.

Author

Landi, Antonio, Alasnag, Mirvat, Heg, Dik, Frigoli, Enrico, Malik, Fazila Tun Nesa, Gomez-Blazquez, Ivan, Pourbaix, Suzanne, Chieffo, Alaide, Spaulding, Christian, Sainz, Fermin, Routledge, Helen, Andò, Giuseppe, Testa, Luca, Sciahbasi, Alessandro, Contractor, Hussain, Jepson, Nigel, Mieres, Juan, Imran, Syed Saqib, Noor, Husam, and Smits, Pieter C.

Published
2024
Full Text
View/download PDF

10. Bivalirudin vs Heparin Anticoagulation in STEMI: Confirmation of the BRIGHT-4 Results.

Author

Stone, Gregg W., Valgimigli, Marco, Erlinge, David, Han, Yaling, Steg, Philippe Gabriel, Stables, Rod H., Frigoli, Enrico, James, Stefan K., Li, Yi, Goldstein, Patrick, Mehran, Roxana, Mehdipoor, Ghazaleh, Crowley, Aaron, Chen, Shmuel, Redfors, Björn, Snyder, Clayton, Zhou, Zhipeng, and Bikdeli, Behnood

Abstract

In the BRIGHT-4 (Bivalirudin With Prolonged Full-Dose Infusion During Primary PCI Versus Heparin Trial-4), anticoagulation with bivalirudin plus a 2- to 4-hour high-dose infusion after percutaneous coronary intervention (PCI) reduced all-cause mortality and bleeding without increasing reinfarction or stent thrombosis compared with heparin alone in patients with ST-segment elevation myocardial infarction (STEMI). These findings require external validation. This study sought to determine outcomes of bivalirudin vs heparin anticoagulation during PCI in STEMI. We performed an individual-patient–data meta-analysis of all large randomized trials of bivalirudin vs heparin in STEMI patients undergoing primary PCI performed before BRIGHT-4. The primary endpoint was all-cause mortality. Six trials randomizing 15,254 patients were included. Pooled across all regimens of bivalirudin and glycoprotein IIb/IIIa inhibitor (GPI) use, bivalirudin reduced 30-day all-cause mortality (2.5% vs 2.9%; adjusted OR: 0.78; 95% CI: 0.62-0.99), cardiac mortality (adjusted OR: 0.69; 95% CI: 0.54-0.88), and major bleeding (adjusted OR: 0.53; 95% CI: 0.44-0.64) but increased reinfarction (adjusted OR: 1.30; 95% CI: 1.02-1.65) and stent thrombosis (adjusted OR: 1.43; 95% CI: 1.05-1.93) compared with heparin. In 4 trials in which 6,244 patients were randomized to bivalirudin plus a high-dose post-PCI infusion vs heparin without planned GPI use (the BRIGHT-4 regimens), 30-day all-cause mortality occurred in 1.8% vs 2.9% of patients, respectively (adjusted OR: 0.74; 95% CI: 0.48-1.12), and bivalirudin reduced cardiac mortality (adjusted OR: 0.62; 95% CI: 0.39-0.97) and major bleeding (adjusted OR: 0.49; 95% CI: 0.35-0.70), with similar rates of reinfarction (adjusted OR: 0.89; 95% CI: 0.58-1.38) and stent thrombosis (adjusted OR: 0.80; 95% CI: 0.41-1.57). In STEMI patients undergoing primary PCI, bivalirudin with a 2- to 4-hour post-PCI high-dose infusion reduced cardiac mortality and major bleeding without an increase in ischemic events compared with heparin monotherapy with provisional GPI use, confirming the BRIGHT-4 results. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results